- Oral presentation
- Open Access
Expression of the human microRNA miR 29a in an Indian cohort of HIV patients
© Dey et al; licensee BioMed Central Ltd. 2014
- Published: 27 May 2014
- Healthy Control Individual
- Host Virus Interaction
- Human microRNA
- Disease Progression Rate
- Indian Cohort
The events during host virus interaction pave the way to differential outcomes in HIV-1 disease progression rates. We have earlier shown that HIV-1Nef gene harbors target sites for the human microRNA, miRNA 29a/b. Over expression of miR 29a/b could reduce virus levels by targeting the Nef gene. We hypothesized that differential expression of the microRNA maybe a protective factor in AIDS progression.
In a cohort of 75 HIV-1 infected individuals, who show differential disease progression, classified as (1) Long Term Non Progressors (LTNPs), (2) Regular Progressors and (3) Rapid Progressors. We isolated RNA and DNA from PBMCs collected from these individuals and healthy controls. We quantified miR 29a expression through Real Time PCR and performed statistical correlation of the miRNA levels with disease progression rate. We further analyzed miR 29a promoter and coding region from selected patients.
Patients, including various sub classes like LTNPs, Regular Progressors and Rapid progressors, had higher miR 29a levels than healthy controls. A small subset of patients had unusually high levels of miR 29a. Three of these individuals were LTNPs while others were classified as regular progressors.
The absence of known genetic causes of non progression like the CCR5 delta mutation, in this patient cohort suggests that there are novel mutations that confer protection. The absence of healthy control individuals with high miR 29a expression suggests that the induction of miRNA maybe happen in response to infection. However, larger sample sizes are required to confirm this. We conclude that miR 29a expression maybe one of the factors that in certain backgrounds provides a better prognosis.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.